A trial conducted out of the University of Chicago is investigating the feasiblity of cediranib maleate and lenalidomide for treating thyroid cancer patients. The primary outcomes of this trial are to determine the ideal dosage of cediranib maleate, its response rate when administered with or without lenalidomide, and determining how well both drugs work together to improve a patient's overall survival. The trial hypothesizes that "cediranib maleate may stop the growth of tumour cells by blocking some of the enzymes needed for cell growth, [while] lenalidomide may stop the growth of thyroid cancer by clocking blood flow to the tumour."
To read more about this trial, click here.
No comments:
Post a Comment